59 results on '"Michael Chaloupka"'
Search Results
2. Transrectal vs. transperineal fusion biopsy of the prostate
- Author
-
Paulo Leonardo Pfitzinger, Benazir Enzinger, Benedikt Ebner, Troya Ivanova, Yannic Volz, Michael Chaloupka, Maria Apfelbeck, and Christian Stief
- Published
- 2023
3. Assessment of single-probe dual-energy lithotripters in percutaneous nephrolithotomy: a systematic review and meta‐analysis of preclinical and clinical studies
- Author
-
Ioannis Mykoniatis, Nikolaos Pyrgidis, Lazaros Tzelves, Amelia Pietropaolo, Patrick Juliebø-Jones, Vincent De Coninck, Belthangady M. Zeeshan Hameed, Michael Chaloupka, Gerald Bastian Schulz, Christian Stief, Panagiotis Kallidonis, Bhaskar K. Somani, and Andreas Skolarikos
- Subjects
Urology - Published
- 2023
4. Sonografie der urogenitalen Organe
- Author
-
Elena K. Berg, Dirk-André Clevert, Maria Apfelbeck, Christian G. Stief, and Michael Chaloupka
- Subjects
General Medicine - Published
- 2022
5. Sonographie der Prostata
- Author
-
Maria Apfelbeck, Dirk-André Clevert, Christian G. Stief, and Michael Chaloupka
- Subjects
Urology ,Obstetrics and Gynecology - Published
- 2022
6. Methylation status of various gene loci in localized prostate cancer: Novel biomarkers for diagnostics and biochemical recurrence
- Author
-
Lennert Eismann, Philipp von Walter, Andreas Jung, Michael Chaloupka, Severin Rodler, Thilo Westhofen, Alexander Buchner, Christian G. Stief, Thomas Stadler, and Boris Schlenker
- Subjects
Oncology ,Urology - Published
- 2023
7. MP61-08 PROSPECTIVE EVALUATION OF RADICAL PROSTATECTOMY WITHOUT PRIOR BIOPSY BASED ON PSA, DRE, MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING AND PROSTATE-SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY
- Author
-
Michael Chaloupka, Maria Apfelbeck, Magnus Idzikowski, and Christian G Stief
- Subjects
Urology - Published
- 2023
8. Adverse Pathology after Radical Prostatectomy of Patients Eligible for Active Surveillance—A Summary 7 Years after Introducing mpMRI-Guided Biopsy in a Real-World Setting
- Author
-
Benedikt Ebner, Maria Apfelbeck, Nikolaos Pyrgidis, Tobias Nellessen, Stephan Ledderose, Paulo Leonardo Pfitzinger, Yannic Volz, Elena Berg, Benazir Enzinger, Severin Rodler, Michael Atzler, Troya Ivanova, Dirk-André Clevert, Christian Georg Stief, and Michael Chaloupka
- Subjects
mpMRI fusion biopsy ,active surveillance ,Bioengineering ,prostate cancer ,upgrading - Abstract
Objective: Over the last decade, active surveillance (AS) of low-risk prostate cancer has been increasing. The mpMRI fusion-guided biopsy of the prostate (FBx) is considered to be the gold standard in preoperative risk stratification. However, the role of FBx remains unclear in terms of risk stratification of low-risk prostate cancer outside high-volume centers. The aim of this study was to evaluate adverse pathology after radical prostatectomy (RP) in a real-world setting, focusing on patients diagnosed with Gleason score (GS) 6 prostate cancer (PCa) and eligible for AS by FBx. Subjects and Methods: Between March 2015 and March 2022, 1297 patients underwent FBx at the Department of Urology, Ludwig-Maximilians-University of Munich, Germany. MpMRI for FBx was performed by 111 different radiology centers. FBx was performed by 14 urologists from our department with different levels of experience. In total, 997/1297 (77%) patients were diagnosed with prostate cancer; 492/997 (49%) of these patients decided to undergo RP in our clinic and were retrospectively included. Univariate and multivariable logistic regression analyses were performed to evaluate clinical and histopathological parameters associated with adverse pathology comparing FBx and RP specimens. To compare FBx and systematic randomized biopsies performed in our clinic before introducing FBx (SBx, n = 2309), we performed a propensity score matching on a 1:1 ratio, adjusting for age, number of positive biopsy cores, and initial PSA (iPSA). Results: A total of 492 patients undergoing FBx or SBx was matched. In total, 55% of patients diagnosed with GS 6 by FBx were upgraded to clinically significant PCa (defined as GS ≥ 7a) after RP, compared to 52% of patients diagnosed by SBx (p = 0.76). A time delay between FBx and RP was identified as the only correlate associated with upgrading. A total of 5.9% of all FBx patients and 6.1% of all SBx patients would have been eligible for AS (p > 0.99) but decided to undergo RP. The positive predictive value of AS eligibility (diagnosis of low-risk PCa after biopsy and after RP) was 17% for FBx and 6.7% for SBx (p = 0.39). Conclusions: In this study, we show, in a real-world setting, that introducing FBx did not lead to significant change in ratio of adverse pathology for low-risk PCa patients after RP compared to SBx.
- Published
- 2023
- Full Text
- View/download PDF
9. [Sonography of the genitourinary system]
- Author
-
Elena K, Berg, Dirk-André, Clevert, Maria, Apfelbeck, Christian G, Stief, and Michael, Chaloupka
- Published
- 2022
10. [Treatment of infected hydronephrosis]
- Author
-
Lennert, Eismann, Christian G, Stief, and Michael, Chaloupka
- Subjects
Pyonephrosis ,Humans ,Hydronephrosis - Published
- 2022
11. Diagnostische Marker in der Urologie
- Author
-
Marie C. Hupe, Axel S. Merseburger, Maria Frantzi, Severin Rodler, Christian G. Stief, Harald Mischak, Michael Chaloupka, and Marie C. Hempel
- Subjects
Nephrology ,Gynecology ,medicine.medical_specialty ,business.industry ,Geriatric care ,Urology ,Non invasive ,030232 urology & nephrology ,Diagnostic marker ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Risk stratification ,medicine ,Liquid biopsy ,business - Abstract
Biomarker konnen die Diagnostik maligner Erkrankungen erganzen. Im Zuge der modernen individualisierten Krebstherapie haben Risikostratifizierung, individuelle Prognose und nicht-invasives Monitoring an Bedeutung gewonnen. In den letzten Jahren ist eine Vielzahl an Biomarkern und zugehoriger Testverfahren hierfur entwickelt worden. Der folgende Ubersichtsartikel fasst die jungsten Entwicklungen bezuglich der Verwendung von Biomarkern in der Diagnostik urologischer Krebserkrankungen zusammen.
- Published
- 2021
12. Nicht metastasiertes Prostatakarzinom: Wann und wie behandeln?
- Author
-
Annika Herlemann, Benedikt Ebner, Christian G. Stief, Michael Chaloupka, Alexander Kretschmer, and Elena Berg
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,MEDLINE ,Treatment options ,General Medicine ,medicine.disease ,Prostate-specific antigen ,Prostate cancer ,Text mining ,Internal medicine ,Medicine ,Stage (cooking) ,business - Published
- 2021
13. Update zur Früherkennung und Diagnostik des Prostatakarzinoms
- Author
-
Alexander Kretschmer, Christian G. Stief, Annika Herlemann, Elena Berg, Benedikt Ebner, and Michael Chaloupka
- Subjects
Oncology ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,MEDLINE ,Magnetic resonance imaging ,General Medicine ,Prostate-specific antigen ,Text mining ,Prostate cancer screening ,Internal medicine ,medicine ,business ,Image-Guided Biopsy ,Mass screening - Published
- 2021
14. Primary Chemotherapy in a 47-Year-Old Patient with Giant Ulcerative and Necrotizing Nonseminomatous Testicular Germ Cell Tumor
- Author
-
Lars H. Lindner, Armin J. Becker, Sophia Stock, Wolfgang G. Kunz, Michael Chaloupka, Julian Walter Holch, Steffen Ormanns, Theresia Pichler, Friederike Mumm, and Julian Marcon
- Subjects
Oncology ,medicine.medical_specialty ,Cancer survivors ,Testicular Germ Cell Tumor ,Case Report ,Bleomycin ,chemistry.chemical_compound ,Internal medicine ,Scrotum ,medicine ,Germ cell tumor ,Orchiectomy ,Etoposide ,Testicular cancer ,RC254-282 ,Ifosfamide ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Psychosocial distress ,medicine.disease ,medicine.anatomical_structure ,chemistry ,business ,Rare disease ,medicine.drug ,Primary chemotherapy - Abstract
Testicular cancer is a rare disease; however, cure rates are high for all tumor stages. Mostly, the disease is diagnosed in an early (local) stage. We report the case of a 47-year-old male patient with a giant nonseminomatous germ cell tumor. At the time of diagnosis, the patient demonstrated a necrotizing and ulcerating growing mass in the left scrotum with an approximate size of 22 × 18 cm. According to the prognostic classification of the International Germ Cell Cancer Collaborative Group (IGCCCG 1997), the patient exhibited a high-risk profile due to alpha-fetoprotein >10,000 ng/mL and lactate dehydrogenase >10× the upper limit of normal in serum. Primary orchiectomy was infeasible due to the tumor’s size, the patient’s poor general condition and initial intensive care unit treatment. Primary systemic chemotherapy was applied. After 3 cycles of cisplatin, etoposide and bleomycin, along with 1 cycle of cisplatin, etoposide and ifosfamide, tumor resection with histomorphological examination showed a complete pathological response. Despite the delayed initiation of the therapy, primary chemotherapy was completed timely and showed promising results. Reasons for the late hospitalization were personal responsibilities regarding his family. Better awareness and knowledge of testicular cancer among young men might prevent the here reported delay of medical consultation and avoid testicular tumors of such enormous size. Psychosocial assessment and distress management is important as an integral part of comprehensive care of testicular cancer patients.
- Published
- 2021
15. Radical Prostatectomy without Prior Biopsy in Patients with High Suspicion of Prostate Cancer Based on Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen Positron Emission Tomography: A Prospective Cohort Study
- Author
-
Michael Chaloupka, Maria Apfelbeck, Nikolaos Pyrgidis, Julian Marcon, Philipp Weinhold, and Christian G. Stief
- Subjects
Cancer Research ,PSMA PET ,Oncology ,mpMRI ,prostate biopsy ,radical prostatectomy - Abstract
Modern risk stratification of prostate cancer (PCa) allows for prediction of advanced disease with a high level of certainty. We aimed to evaluate a prospective series of patients undergoing radical prostatectomy without prior biopsy based solely on clinical criteria and imaging results. The patients were divided into three groups. Group 1 included 27 patients with: (i) suspicious digital rectal examination, (ii) PSA ≥ 10 ng/mL, (iii) PI-RADS 4/5 on mpMRI, and (iv) high suspicion of PCa on PSMA-PET. Group 2 included six patients who fulfilled criteria i, ii, and iii but did not undergo PSMA-PET imaging. Group 3 included 17 patients with at least one clinical (i or ii) and one imaging (iii or iv) criterion. All of the patients were diagnosed with PCa. Comparison of Group 1 and 2 versus Group 3 showed a significantly higher ratio of locally advanced PCa for Groups 1 and 2 compared to Group 3 (60.6% versus 11.8%, p = 0.005, respectively). Similarly, these patients displayed a significantly higher ratio of aggressive PCa (ISUP grade > 2: 66.7% versus 23.5%, p = 0.027, respectively) and tumor infiltration (median tumor infiltration: 32.5% vs. 15%, p = 0.001, respectively) in the final specimen compared to Group 3. In conclusion, we have shown that radical prostatectomy without prior biopsy is safe in terms of the diagnosis of clinically significant PCa when proper preoperative risk stratification involving mpMRI and PSMA-PET imaging is applied.
- Published
- 2023
16. Predictive clinical features for negative histopathology of MRI/Ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: Analysis from a urologic outpatient clinic1
- Author
-
Maria Apfelbeck, Christian G. Stief, Dirk-André Clevert, Robert Bischoff, Jan-Niklas Mumm, Paulo Pfitzinger, Alexander Buchner, Lukas Rath, Michael Chaloupka, and Boris Schlenker
- Subjects
Image-Guided Biopsy ,Male ,medicine.medical_specialty ,Prostate biopsy ,Physiology ,030218 nuclear medicine & medical imaging ,Lesion ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Prostate ,Physiology (medical) ,Outpatients ,Biopsy ,medicine ,Humans ,Aged ,Retrospective Studies ,Ultrasonography ,medicine.diagnostic_test ,Index Lesion ,Receiver operating characteristic ,business.industry ,Prostatic Neoplasms ,Hematology ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Female ,Histopathology ,Radiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business - Abstract
OBJECTIVE: The aim of this study was to evaluate clinical features associated with benign histopathology of Prostate Imaging Reporting and Data System (PI-RADS) category 4 and 5 lesions. MATERIALS AND METHODS: Between March 2015 and November 2020, 1161 patients underwent mpMRI/Ultrasound-fusion-guided prostate biopsy (FBx) and concurrent 12-core systematic prostate biopsy (SBx) at the Department of Urology of the Ludwig-Maximilians-University of Munich, Germany. 848/ 1161 (73%) patients presented with either PI-RADS 4 or 5 index lesion and were retrospectively evaluated. Multivariate analysis was performed to evaluate clinical parameters associated with a negative outcome of PI-RADS 4 or 5 category lesions after FBx. Area under the receiver operating characteristics (ROC) curve (AUC) was conducted using ROC-analysis. RESULTS: 676/848 (79.7%) patients with either PI-RADS 4 or 5 index lesion were diagnosed with prostate cancer (PCa) by FBx and 172/848 (20.3%) patients had a negative biopsy (including the concurrent systematic prostate biopsy), respectively. Prostate volume (P-Vol) (OR 0.99, 95% CI = 0.98–1.00, p = 0.038), pre-biopsy-status (OR 0.48, 95% CI = 0.29–0.79, p = 0.004) and localization of the lesion in the transitional zone (OR 0.28, 95% CI = 0.13–0.60, p = 0.001) were independent risk factors for a negative outcome of FBx. Age (OR 1.09, 95% CI = 1.05–1.13, p
- Published
- 2021
17. Five-Year Results of a Prospective Multicenter Trial: AdVance XP for Postprostatectomy-Incontinence in Patients with Favorable Prognostic Factors
- Author
-
Theresa Vilsmaier, Ricarda M. Bauer, Alexander Kretschmer, Markus Grabbert, Benedikt Klehr, Christian Gozzi, Gerald Schulz, Florian May, Michael Chaloupka, Peter Rehder, Christian G. Stief, Thilo Westhofen, Severin Rodler, Jan-Niclas Mumm, and Roland Homberg
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Urology ,030232 urology & nephrology ,Urine ,Sling (weapon) ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Quality of life ,Multicenter trial ,medicine ,Humans ,Prospective Studies ,Aged ,Aged, 80 and over ,Prostatectomy ,Suburethral Slings ,business.industry ,Visual Analog Pain Scale ,Middle Aged ,Prognosis ,Surgery ,Treatment Outcome ,Urinary Incontinence ,Urethra ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,International Prostate Symptom Score ,business ,Complication ,Follow-Up Studies - Abstract
Objective: The aim of this study was to assess the security, value, and efficacy of the second-generation AdVance male sling XP (Boston Scientific®), after implementation in 2010 with advantageous modifications in the sling structure and needle shape, in a prospective multicenter long-term follow-up study. Methods: In total, 115 patients were included. Exclusion criteria were earlier incontinence (UI) surgery, nocturnal UI, former radiotherapy, or night-time incontinence. We also excluded patients with a functional urethra Results: The 24-month follow-up (114 patients) revealed 64.0% cured and 28.8% improved patients. Mean urine loss was reduced significantly to 19.0 g (p < 0.001). A mean PGI score of 1.5 and a mean VAS score of 0.2 were obtained. The 60-month follow-up (59 patients) revealed 57.6% cured and 25.4% improved patients. Mean urine loss was reduced significantly to 18.3 g (p < 0.001). A mean PGI score of 1.6 and a mean VAS score of 0.2 were obtained. Conclusions: The AdVance XP displays excellent continence results and secure effectiveness over a 5-year period. Moreover, these data are demonstrating low complication rates and improved quality of life in the long-term use of AdVance XP.
- Published
- 2021
18. Does Pandemic Anxiety Affect Urology Health Care Workers?
- Author
-
Maria Apfelbeck, Regina Stredele, Christian G. Stief, Jozefina Casuscelli, Severin Rodler, Michael Chaloupka, Alexander Buchner, Michael Staehler, and Jan Niclas Mumm
- Subjects
Male ,medicine.medical_specialty ,Health Personnel ,Urology ,education ,Anxiety ,Mental distress ,Personal protective equipment ,Surveys and Questionnaires ,Health care ,Pandemic ,medicine ,Transmission ,Humans ,Pandemics ,Original Paper ,Health care workers ,SARS-CoV-2 ,business.industry ,Risk of infection ,virus diseases ,COVID-19 ,Workload ,Distress ,Cross-Sectional Studies ,Female ,medicine.symptom ,business - Abstract
Purpose: To assess anxiety, stress level, and perception of safety during the coronavirus disease 2019 (COVID-19) pandemic in health care workers (HCWs) of one of Germany’s largest urology university clinics. Methods: A cross-sectional study among urological HCWs was performed. HCWs were surveyed for anxiety about the pandemic, stress level and current workload, fear of coronavirus infection, current perception of safety at work, and attitude towards protective equipment and tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Results: Sixty-three HCWs filled in the questionnaire. Overall anxiety of infection with COVID-19 is at a median of 4.7 with no statistically significant difference between nurses and physicians (p = 0.0749). Safety at work reaches a median of 6 out of 10. In fact, the highest fear in 56.7% (31/63) of the personnel is to get infected by a colleague tested positive for SARS-CoV-2 despite wearing surgical face masks. A proportion of 55.7 and 74.6% highly favor swabs for SARS-CoV-2 on a regular basis in HCWs and patients, respectively (p = 0.0001). Workload in the urology department is clearly reduced during the pandemic (physicians 39.3% vs. nurses 32.2%, p = 0.0001) and 57.4% do not feel distress at all; only 27.9% express mental distress. Conclusion: During the pandemic, urology HCWs perceive lower burden by workload and deem themselves at low risk of infection. However, the greatest anxiety is related to infection by a SARS-CoV-2-positive colleague, despite reciprocal protection by surgical face masks. This highlights a relevant mental stress and uncertainty towards management of infected HCWs, calling for increased education and psychological support.
- Published
- 2021
19. Listening to Music during Outpatient Cystoscopy Reduces Pain and Anxiety and Increases Satisfaction: Results from a Prospective Randomized Study
- Author
-
Maria Apfelbeck, Yannic Volz, Michael Staehler, Ricarda M. Bauer, Michael Chaloupka, Alaleh Zati Zehni, Jan-Niclas Mumm, Christian G. Stief, Lennert Eismann, Theresa Vilsmaier, Paulo Pfitzinger, and Severin Rodler
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Attitude of Health Personnel ,Visual analogue scale ,Urologists ,Urology ,Beck Anxiety Inventory ,Pain ,Anxiety ,law.invention ,Patient satisfaction ,Randomized controlled trial ,law ,Germany ,Ambulatory Care ,Humans ,Medicine ,Prospective Studies ,Music Therapy ,Aged ,Pain Measurement ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Cystoscopy ,Middle Aged ,Cystoscopies ,humanities ,Distress ,Treatment Outcome ,Patient Satisfaction ,Physical therapy ,Female ,medicine.symptom ,business - Abstract
Background: This study investigates the effect of classical music, music of patients’ own choice, or no music on pain reduction during elective cystoscopy. Objectives: The aim of the study was to describe the effect of listening to classical music, music of patients’ own choice, or no music on patient’s pain and satisfaction rates when carrying out an elective cystoscopy and the effect on the assessment capability of the performing urologist. Design, Setting, and Participants: This randomized trial included 127 patients undergoing elective cystoscopy at the Urological Department of the University Clinic of Munich between June 2019 and March 2020. Outcome Measurements and Statistical Analysis: Patients were assigned randomly to 3 groups: group I: listening to standardized classical music (n = 35), group II: listening to music according to the patients’ choice (n = 34), and control group III: no music (n = 44). Prior to cystoscopy, anxiety levels were assessed by the Beck Anxiety Inventory (BAI). The Visual Analog Scale (VAS, range 1–100) was used for a self-assessment of pain, discomfort, and satisfaction. Statistical analysis was done with Spearman’s rank correlation and t-tests. Results and Limitations: The median age was 63 (range 27–91) years. The duration of cystoscopy was 5.7 (1–30) min. Patients had undergone a median of 2.3 cystoscopies in the past. Between giving informed consent and cystoscopy, patients had to wait for a median of 64 (0–260) min. The median VAS pain score was significantly lower in group I at 1.7 and group II at 2.3 versus 5.2 in the control group III (p < 0.001). The control group III had significantly worse pain and patient satisfaction rates compared with groups I and II. Group I had a significant lower VAS pain score than groups II and III (p < 0.001). Classical music also increased the assessment capability of the preforming urologist. Conclusions: Listening to music during elective cystoscopy significantly reduces pain and distress and leads to higher patient and surgeon satisfaction. We recommend listening to classical music or music chosen by the patients during outpatient flexible/rigid cystoscopy in daily clinical routine. Patient Summary: In this study, we found that patients who listened to classical music or music of their own choice while undergoing a cystoscopy showed significant reduction of pain and distress.
- Published
- 2021
20. PSA-Test: Sinn oder Unsinn?
- Author
-
Alexander Kretschmer, Maria Apfelbeck, Christian G. Stief, and Michael Chaloupka
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,medicine ,MEDLINE ,General Medicine ,business - Published
- 2020
21. Multiparametric magnetic resonance imaging and multiparametric magnetic resonance imaging-guided biopsy in the diagnostic pathway of prostate cancer
- Author
-
Maria Apfelbeck, Robert Bischoff, Christian G. Stief, E. Lellig, Dirk-André Clevert, Lukas Rath, Michael Chaloupka, Boris Schlenker, and Paulo Pfitzinger
- Subjects
Image-Guided Biopsy ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Prostate ,Biopsy ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Multiparametric Magnetic Resonance Imaging ,Cardiac imaging ,Neuroradiology ,medicine.diagnostic_test ,business.industry ,Prostatectomy ,Ultrasound ,Prostatic Neoplasms ,medicine.disease ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Radiology ,business - Abstract
Multiparametric magnetic resonance imaging (mpMRI) of the prostate and mpMRI-guided biopsy have proved to be a valuable part of the diagnostic pathway for prostate cancer. This review reports on the current results in terms of clinical performance of these diagnostic tools and their role in clinical decision-making.Die multiparametrische Magnetresonanztomographie (mpMRT) der Prostata und die mpMRT-gesteuerte Biopsie sind ein wichtiger Bestandteil der Diagnostik des Prostatakarzinoms. In dieser Übersichtsarbeit berichten wir über die aktuelle Studienlage zur klinischen Anwendung dieser diagnostischen Mittel und bewerten deren Stellenwert in der klinischen Entscheidungsfindung.
- Published
- 2020
22. Impact of previous transurethral prostate surgery on health-related quality of life after radical prostatectomy: Does the interval between surgeries matter?
- Author
-
Michael Chaloupka, Franka Figura, Philipp Weinhold, Friedrich Jokisch, Thilo Westhofen, Paulo Pfitzinger, Robert Bischoff, Giuseppe Magistro, Frank Strittmatter, Armin Becker, Steffen Ormanns, Boris Schlenker, Alexander Buchner, Christian G. Stief, and Alexander Kretschmer
- Subjects
Laser vaporization of the prostate ,03 medical and health sciences ,0302 clinical medicine ,Health-related quality of life ,Laser enucleation of the prostate ,030220 oncology & carcinogenesis ,Urology ,Robot-assisted radical prostatectomy ,030232 urology & nephrology ,Transurethral resection of the prostate ,Original Article ,EORTC QLQ-C30 ,Radical prostatectomy - Abstract
Purpose To assess the impact of previous transurethral surgery for benign prostate enlargement (BPE) and time interval between procedures on functional outcomes and health-related quality of life (HRQOL) after radical prostatectomy (RP). Methods A propensity score-matched patient cohort [n = 685, (513 without previous BPE surgery, 172 with BPE surgery)] was created and HRQOL was pre- and postoperatively assessed using validated questionnaires (EORTC QLQ-C30). Urinary continence was measured via ICIQ-SF questionnaire and pad usage. Multivariable analysis included binary logistic and Cox regression models (p Results Median follow-up was 18 months. There was no significant difference in recurrence-free survival in multivariate analysis (HR 0.66, 95%CI 0.40–1.07, p = 0.093). We observe higher mean ICIQ-SF scores (5.7 vs. 8.2, p p p p = 0.003). In multivariate analysis, continence recovery (OR 5.19, 95%CI 3.10–8.68, p p = 0.806) could be identified as independent predictors of good general HRQOL. There was no significant correlation between time interval between both surgeries and continence (p = 0.408), and HRQOL (p = 0.386) outcomes. Conclusions We observe favourable continence outcomes for patients without previous BPE surgery. Our results indicate that RP can be safely performed after transurethral BPE surgery, regardless of the time interval between both interventions.
- Published
- 2020
23. Health-related quality of life after open and robot-assisted radical prostatectomy in low- and intermediate-risk prostate cancer patients: a propensity score-matched analysis
- Author
-
Alexander Kretschmer, Michael Chaloupka, Alexander Buchner, Frank Strittmatter, Philipp Weinhold, Robert Bischoff, Thilo Westhofen, Armin J. Becker, Christian G. Stief, and Friedrich Jokisch
- Subjects
medicine.medical_specialty ,Urology ,medicine.medical_treatment ,Health-related quality of life ,030232 urology & nephrology ,Logistic regression ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Quality of life ,Internal medicine ,Clinical endpoint ,Robot-assisted radical prostatectomy ,Medicine ,Urinary continence ,business.industry ,Prostatectomy ,EORTC QLQ-C30 ,medicine.disease ,humanities ,030220 oncology & carcinogenesis ,Cohort ,Propensity score matching ,Original Article ,business ,Open radical prostatectomy - Abstract
Purpose Introduction of robot-assisted radical prostatectomy (RARP) has revolutionized the therapeutic landscape of organ-confined prostate cancer (PCa). However, comparative analyses focused on health-related quality of life (HRQOL) after RARP and open retropubic prostatectomy (ORP) are sparse. Methods In the current retrospective analysis,inclusion criteria encompassed PSA ≤ 10 ng/ml, ≤ pT2c, ISUP ≤ 3, age ≤ 65 years, and preoperative continence. A propensity score-matched patient cohort [n = 418 (ORP: 209, RARP: 209)] was created and HRQOL was prospectively assessed based on validated questionnaires (EORTC QLQ-C30) preoperatively, 3 months, 12 months, and 24 months postoperatively. Primary endpoint was good general HRQOL based on previously published cut-off values. Erectile function was measured via IIEF-5, urinary continence via ICIQ-SF questionnaire. Multivariable analysis included binary logistic regression models (p
- Published
- 2020
24. [Sonography of the prostate : Relevance for urologists in daily clinical routine]
- Author
-
Maria, Apfelbeck, Dirk-André, Clevert, Christian G, Stief, and Michael, Chaloupka
- Subjects
Image-Guided Biopsy ,Male ,Urologists ,Prostate ,Humans ,Prostatic Neoplasms ,Prospective Studies ,Magnetic Resonance Imaging ,Ultrasonography - Abstract
Despite the continuous technical progress regarding the transrectal ultrasonography of the prostate (TRUS) and its successful use in combination with magnetic resonance imaging (MRI) in MRI-targeted biopsy, there is no radiologic modality being able to rule out clinically significant prostate cancer without the need of systematic biopsy. In the past few years, TRUS regained more attention due to the development of high frequency ultrasound as well as the combination of different ultrasonic modalities like shear wave elastography and contrast-enhanced sonography (CEUS). Currently, multiparametric MRI (mpMRI)-targeted biopsy shows the best results concerning detection rates, sensitivity and specificity of clinically significant prostate cancer compared to systematic biopsy. In the future, transperineal biopsy is probably going to increasingly replace the transrectal biopsy approach. For both approaches, transrectal ultrasonography is necessary to display the prostate and to detect suspicious lesions. Therefore future improvements in transrectal ultrasonography can be expected.Trotz der kontinuierlichen Weiterentwicklung des transrektalen Ultraschalls (TRUS) und der Kombination verschiedener Bildgebungsmodalitäten gibt es aktuell noch kein Verfahren, das die systematische Biopsie der Prostata obsolet macht und eine alleinige läsionsgesteuerte Biopsie zulässt. Durch die Weiterentwicklung des konventionellen TRUS durch höhere Schallfrequenzen sowie die Kombination verschiedener Ultraschallmodalitäten (z. B. der Scherwellenelastographie und dem kontrastmittelgestütztem Ultraschall) rückt der transrektale Ultraschall zur Diagnostik des Prostatakarzinoms wieder zunehmend in den Fokus. Aktuell hat jedoch die multiparametrisch magnetresonanztomographisch (mpMRT) gestützte Target-Biopsie zusammen mit der systematischen Biopsie die beste Datenlage bezüglich einer Verbesserung der Detektionsrate von klinisch signifikantem Prostatakrebs im Vergleich zur alleinigen randomisierten Biopsie. Bezüglich des Biopsiezugangs wird voraussichtlich die transrektale Biopsie durch den transperinealen Zugang immer mehr in den Hintergrund geraten. Der TRUS wird jedoch in beiden Zugangswegen verwendet, weswegen von einer fortschreitenden Weiterentwicklung auszugehen ist.
- Published
- 2022
25. SFRP2 Overexpression Induces an Osteoblast-like Phenotype in Prostate Cancer Cells
- Author
-
Elif Akova Ölken, Attila Aszodi, Hanna Taipaleenmäki, Hiroaki Saito, Veronika Schönitzer, Michael Chaloupka, Maria Apfelbeck, Wolfgang Böcker, and Maximilian Michael Saller
- Subjects
General Medicine ,SFRP2 ,osteomimicry ,prostate cancer ,PC3 ,bone metastasis ,EMT ,WNT signaling - Abstract
Prostate cancer bone metastasis is still one of the most fatal cancer diagnoses for men. Survival of the circulating prostate tumor cells and their adaptation strategy to survive in the bone niche is the key point to determining metastasis in early cancer stages. The promoter of SFRP2 gene, encoding a WNT signaling modulator, is hypermethylated in many cancer types including prostate cancer. Moreover, SFRP2 can positively regulate osteogenic differentiation in vitro and in vivo. Here, we showed SFRP2 overexpression in the prostate cancer cell line PC3 induces an epithelial mesenchymal transition (EMT), increases the attachment, and modifies the transcriptome towards an osteoblast-like phenotype (osteomimicry) in a collagen 1-dependent manner. Our data reflect a novel molecular mechanism concerning how metastasizing prostate cancer cells might increase their chance to survive within bone tissue.
- Published
- 2022
26. Neue Therapieoptionen beim fortgeschrittenen Prostatakarzinom
- Author
-
Annika Herlemann, Christian G. Stief, Michael Chaloupka, Thilo Westhofen, Alexander Kretschmer, and Tilman Todenhöfer
- Subjects
Oncology ,medicine.medical_specialty ,Prostate cancer ,Text mining ,business.industry ,Internal medicine ,medicine ,General Medicine ,medicine.disease ,business - Published
- 2021
27. Notfall: Infizierte Harnstauungsniere
- Author
-
Lennert Eismann, Christian G. Stief, and Michael Chaloupka
- Subjects
General Medicine - Published
- 2022
28. [Diagnostic markers in urology]
- Author
-
Marie C, Hupe, Marie C, Hempel, Severin, Rodler, Maria, Frantzi, Harald, Mischak, Axel S, Merseburger, Christian G, Stief, and Michael, Chaloupka
- Subjects
Urologic Neoplasms ,Urology ,Biomarkers, Tumor ,Humans ,Prognosis ,Biomarkers - Abstract
Cancer diagnostics can be supplemented by disease-related biomarkers. In the course of modern patient-tailored cancer treatment, the importance of correct risk stratification, prognosis and monitoring has significantly increased. In recent years, a multitude of biomarkers and related test procedures have emerged to fulfil this purpose. The following review article summarizes the most recent developments with respect to the use of biomarkers in the diagnostics of urological cancers.Biomarker können die Diagnostik maligner Erkrankungen ergänzen. Im Zuge der modernen individualisierten Krebstherapie haben Risikostratifizierung, individuelle Prognose und nicht-invasives Monitoring an Bedeutung gewonnen. In den letzten Jahren ist eine Vielzahl an Biomarkern und zugehöriger Testverfahren hierfür entwickelt worden. Der folgende Übersichtsartikel fasst die jüngsten Entwicklungen bezüglich der Verwendung von Biomarkern in der Diagnostik urologischer Krebserkrankungen zusammen.
- Published
- 2021
29. Comparison of PIRADS 3 lesions with histopathological findings after MRI-fusion targeted biopsy of the prostate in a real world-setting
- Author
-
Dirk-André Clevert, C.G. Stief, Maria Apfelbeck, Marco Armbruster, Boris Schlenker, and Michael Chaloupka
- Subjects
Image-Guided Biopsy ,Male ,Target lesion ,medicine.medical_specialty ,Physiology ,030204 cardiovascular system & hematology ,Targeted biopsy ,030218 nuclear medicine & medical imaging ,Lesion ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Prostate ,Physiology (medical) ,medicine ,Humans ,Aged ,Aged, 80 and over ,business.industry ,Ultrasound ,Prostatic Neoplasms ,Cancer ,Multiparametric MRI ,Hematology ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,medicine.anatomical_structure ,Radiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business - Abstract
Introduction We aimed to evaluate whether PIRADS 3 lesions in multiparametric MRI (mpMRI) represent a significant risk of prostate cancer (PCa) in a real-world setting of different referring radiologic institutes. Materials and methods Between May 2015 and October 2017, a total of 408 patients were referred to our clinic for MRI-ultrasound fusion targeted biopsy of the prostate (FusPbx) due to suspected prostate cancer. In all patients, preoperatively an mpMRI of the prostate was performed by altogether 62 different radiologic institutes. Prostate lesions were classified according to the PIRADS system. A PIRADS 3 lesion was diagnosed in 41 patients. FusPbx was performed transrectally using a Philips EPIQ 7 (Philips Medical Systems, Bothell, WA) scanner with plane wise fusion of ultrasound and MRI image data. In addition to FusPbx in each patient a randomized 12-core transrectal ultrasound guided biopsy (USPbx) was performed. Results Mean PSA Level was 9.5 ng/ml (range: 1- 26 ng/ml), mean patients age was 66.1 years (48.6- 80.4). In 11/41 patients (26.8%) prostate cancer was diagnosed by FusPbx of the PIRADS 3 lesion. In the target lesion PCa was classified as Gleason Score 3+3 in 5 patients, as 3+4 in 3, 4+3 in 1, 4+4 in 1 and 4+5 in 1 patient. In patients with negative FusPbx USPbx revealed PCa in another 7 patients (17.1%). In 5 of these GS 3+3 PCa was found, in another 2 patients GS 3+4 PCa. Conclusions PIRADS 3 lesion indicates an equivocal likelihood of significant prostate cancer. In our series the overall PCa detection rate was 26.8% and 14.6% for clinically significant cancer in PIRADS 3 lesions. This evokes the question, if PIRADS 3 lesions could be surveilled only. The findings should be confirmed in a larger series.
- Published
- 2019
30. Aktuelle Kontroversen in der Therapie des lokal begrenzten Prostatakarzinoms
- Author
-
Tobias Grimm, Philipp Weinhold, Thilo Westhofen, Robert Bischoff, Alexander Kretschmer, Derya Tilki, Boris Schlenker, C.G. Stief, and Michael Chaloupka
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Urology ,medicine.medical_treatment ,Brachytherapy ,030232 urology & nephrology ,medicine.disease ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Medicine ,business - Abstract
In der PSA-Ara (prostataspezifisches Antigen) werden die meisten Prostatakarzinome (PCA) im lokal begrenzten Stadium detektiert. In diesem Stadium stehen dem behandelnden Arzt zahlreichende konservative, organerhaltende, strahlentherapeutische und operative Therapieverfahren zur Verfugung, welche oftmals konkurrieren. In der aktuellen narrativen Ubersichtsarbeit geben wir einen Uberblick uber zahlreiche aktuelle Kontroversen in der Therapie des lokal begrenzten PCA und legen aktuell publizierte Studien zu der jeweiligen Thematik dar. Der Fokus wird hierbei auf fokale organerhaltende Therapien, die perkutane Strahlentherapie sowie operative Therapieverfahren gelegt.
- Published
- 2019
31. Active Surveillance beim Prostatakarzinom
- Author
-
Thilo Westhofen, Michael Chaloupka, Maria Apfelbeck, Alexander Kretschmer, Tobias Grimm, and Christian G. Stief
- Subjects
Gynecology ,03 medical and health sciences ,medicine.medical_specialty ,0302 clinical medicine ,Oncology ,business.industry ,030220 oncology & carcinogenesis ,Urology ,030232 urology & nephrology ,medicine ,business ,Fusion Biopsy ,030215 immunology - Abstract
Das Prostatakarzinom ist eine heterogene Erkrankung. Im Falle eines Niedrigrisikokarzinoms stellt die aktive Uberwachung eine attraktive Therapiealternative dar. Einschneidende Komplikationen einer definitiven Therapie konnen somit aufgeschoben bzw. ganz vermieden werden. Trotz strenger Einschlusskriterien fur die aktive Uberwachung ist die Diagnose eines Niedrigrisikokarzinoms aber nicht immer korrekt gestellt. Es verbleibt ein Risiko, dass der optimale Zeitpunkt einer definitiven Therapie verpasst wird. Eine multimodale Diagnostik sowie eine engmaschige Nachsorge sind deswegen essenziell.
- Published
- 2019
32. Management von Harnleiterverletzungen
- Author
-
Vincent Beck, Alexander Kretschmer, Frank Strittmatter, Stefan Tritschler, Michael Chaloupka, and Stephan Ledderose
- Subjects
Gynecology ,03 medical and health sciences ,medicine.medical_specialty ,0302 clinical medicine ,medicine.diagnostic_test ,business.industry ,Urology ,030232 urology & nephrology ,medicine ,030208 emergency & critical care medicine ,Computed tomography ,business ,Retrograde ureteropyelography - Abstract
Harnleiterverletzungen machen weniger als 3 % der Traumata im Urogenitaltrakt aus. Sie entstehen meist iatrogen wahrend operativer Eingriffe im Bauchraum. Die Symptome sind unspezifisch und fur die Diagnosestellung wenig hilfreich. Je spater die Verletzung erkannt wird, desto haufiger kommt es zu Komplikationen. Daher ist es wichtig, bei entsprechender Anamnese an die Moglichkeit einer Harnleiterverletzung zu denken und weiterfuhrende Diagnostik zu veranlassen. Verschiedene diagnostische Methoden stehen zur Verfugung. Neben der direkten Inspektion der Ureteren und der retrograden Ureteropyelographie hat sich die Computertomographie-Urographie etabliert. Abhangig vom Zeitpunkt der Diagnosestellung, dem Ausmas und der Lokalisation der Verletzung wird das Prozedere festgelegt. Bei geringgradigen Verletzungen ist meist die Einlage einer Harnleiterschiene Therapie der Wahl, bei hohergradigen muss eine operative Rekonstruktion erfolgen, wobei verschiedene Operationsverfahren Anwendung finden.
- Published
- 2019
33. [Advanced prostate cancer - modern therapies, better prognosis?]
- Author
-
Thilo, Westhofen, Michael, Chaloupka, Annika, Herlemann, Tilman, Todenhöfer, Christian G, Stief, and Alexander, Kretschmer
- Subjects
Male ,Humans ,Prostatic Neoplasms ,Prognosis - Published
- 2021
34. [Prostate cancer: Screening, imaging, targeted diagnostics]
- Author
-
Elena, Berg, Benedikt, Ebner, Annika, Herlemann, Christian G, Stief, Alexander, Kretschmer, and Michael, Chaloupka
- Subjects
Image-Guided Biopsy ,Male ,Humans ,Mass Screening ,Prostatic Neoplasms ,Prostate-Specific Antigen ,Magnetic Resonance Imaging ,Early Detection of Cancer - Published
- 2021
35. [Prostate cancer: When to treat, which treatment options by stage?]
- Author
-
Benedikt, Ebner, Michael, Chaloupka, Elena, Berg, Christian G, Stief, Alexander, Kretschmer, and Annika, Herlemann
- Subjects
Male ,Humans ,Prostatic Neoplasms ,Prostate-Specific Antigen - Published
- 2021
36. A matter of size? Health-related quality of life after radical prostatectomy for patients with giant prostates
- Author
-
Alexander Kretschmer, Armin J. Becker, Robert Bischoff, Alexander Buchner, Christian G. Stief, Thilo Westhofen, Boris Schlenker, and Michael Chaloupka
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,Logistic regression ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Surveys and Questionnaires ,Clinical endpoint ,Medicine ,Humans ,Aged ,Prostatectomy ,Proportional hazards model ,business.industry ,Hazard ratio ,Prostate ,Prostatic Neoplasms ,Odds ratio ,Middle Aged ,humanities ,Confidence interval ,Survival Rate ,030104 developmental biology ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Quality of Life ,business - Abstract
BACKGROUND Evidence regarding the impact of giant prostate volume (PV) on outcome after radical prostatectomy (RP) is controversial with a lack of evidence on the impact of PV on health-related quality of life (HRQOL). We aimed to assess the impact of giant PV on HRQOL and functional outcomes for men with prostate cancer (PC) undergoing RP. METHODS Giant PV was defined based on the 95th percentile of PV measured by specimen weight of 3929 patients that underwent RP between 2013 and 2018 in a large tertiary care center. A propensity score-matched analysis of 929 men treated with RP for PC (n = 184 with PV ≥ 100 cm3 , n = 745 with PV
- Published
- 2021
37. [Treatment of acute renal colic]
- Author
-
Lennert, Eismann, Christian G, Stief, and Michael, Chaloupka
- Subjects
Acute Disease ,Humans ,Kidney Diseases ,Renal Colic - Published
- 2021
38. Postoperative change in Gleason score of prostate cancer in fusion targeted biopsy: a matched pair analysis
- Author
-
Alexander Kretschmer, Boris Schlenker, Maria Apfelbeck, Stefan Tritschler, Dirk-André Clevert, C.G. Stief, Annika Herlemann, Alexander Buchner, and Michael Chaloupka
- Subjects
Oncology ,Image-Guided Biopsy ,Male ,Matched Pair Analysis ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,Matched-Pair Analysis ,030232 urology & nephrology ,030204 cardiovascular system & hematology ,Targeted biopsy ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Postoperative Period ,Ultrasonography, Interventional ,Aged ,Retrospective Studies ,Prostatectomy ,business.industry ,Ultrasound ,Prostatic Neoplasms ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Nephrology ,sense organs ,Biopsy, Large-Core Needle ,Neoplasm Grading ,business - Abstract
To evaluate if MRI/ultrasound fusion based targeted biopsy (FBx) leads to a reduced rate of change in Gleason score (GS) compared to prostatectomy specimen.The histopathological findings of the biopsy of the prostate and the radical prostatectomy (RP) specimen of 210 patients who were referred to our hospital between 2012 and 2017 were compared retrospectively in this study. One hundred and five patients who underwent FBx combined with ultrasound-guided 12-core biopsy of the prostate (SBx) were matched with 105 patients who underwent SBx only. This study evaluated the rate of up- or downgrading in the RP specimen in both groups and compared the resultsConcordance in Gleason grade group (GGG) was found in 52/105 patients (49.5%) in SBx and in 49/105 patients (46.7%) with FBx (FBx does not decrease the rate of upgrading between biopsy and final pathology in RP specimens. Our results indicate that FBx tends to overestimate the final GGG compared to SBx.
- Published
- 2021
39. Multiparametric MRI Lesion Classified as Prostate Imaging-Reporting and Data System 5 but Histopathologically Described as Benign: A Case Report and Review of Literature
- Author
-
Boris Schlenker, Christian G. Stief, Maria Apfelbeck, Michael Chaloupka, and Dirk-André Clevert
- Subjects
Male ,medicine.medical_specialty ,business.industry ,Urology ,Ultrasound ,Multiparametric MRI ,Cancer ,Prostatic Neoplasms ,Malignancy ,medicine.disease ,Lesion ,Prostate cancer ,medicine.anatomical_structure ,Prostate ,Research Design ,Medicine ,Data Systems ,Humans ,Histopathology ,Radiology ,medicine.symptom ,Multiparametric Magnetic Resonance Imaging ,business ,Aged - Abstract
Introduction: Prostate cancer (PCa) is the most common malignancy in men. The multiparametric MRI (mpMRI) significantly improved the diagnostic approach of PCa. Although PCa is highly likely to be present in prostate imaging-reporting and data system (PI-RADS) 5 lesions, there are up to 18% of PI-RADS 5 lesions with benign histopathology after targeted biopsy. Case Description: We present the case of a 66-year-old man who was referred to our hospital for MRI/ultrasound fusion-based targeted biopsy due to an elevated PSA and a PI-RADS 5 lesion described in the mpMRI. After 2 consecutive biopsies, the mpMRI target showed no malignancy. The lesion was described as PI-RADS 2 two years later. Conclusion: This case demonstrates the risk of false-positive classified PI-RADS 5 lesions in the mpMRI and the challenge in some cases to distinguish between BPH nodules and cancer. Until today, a limited amount of studies exists concerning this issue. However, further studies are required to evaluate further characteristics associated with a higher possibility of histopathologically benign findings in PI-RADS 5 lesions.
- Published
- 2020
40. MP74-14 HEALTH-RELATED QUALITY OF LIFE AFTER OPEN AND ROBOT-ASSISTED RADICAL PROSTATECTOMY: A PROPENSITY SCORE MATCHED ANALYSIS
- Author
-
Philipp Weinhold, Robert Bischoff, Frank Strittmatter, Alexander Buchner, Christian G. Stief, Michael Chaloupka, Friedrich Jokisch, Armin J. Becker, Thilo Westhofen, and Alexander Kretschmer
- Subjects
Oncology ,Health related quality of life ,medicine.medical_specialty ,Prostate cancer ,Prostatectomy ,business.industry ,Urology ,Internal medicine ,medicine.medical_treatment ,Propensity score matching ,medicine ,medicine.disease ,business - Abstract
INTRODUCTION AND OBJECTIVE:Introduction of robot-assisted radical prostatectomy (RARP) has revolutionized the therapeutic landscape of organ confined prostate cancer (PCa) over the last two decades...
- Published
- 2020
41. Prospective evaluation of 4-D contrast-enhanced-ultrasound (CEUS) imaging in bladder tumors
- Author
-
Alexander Buchner, Paulo Pfitzinger, Boris Schlenker, Friedrich Jokisch, Michael Chaloupka, Gerald Schulz, C.G. Stief, Philipp Weinhold, Dirk-André Clevert, and Tobias Grimm
- Subjects
Male ,medicine.medical_specialty ,Physiology ,Image quality ,Contrast Media ,030204 cardiovascular system & hematology ,Prospective evaluation ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Physiology (medical) ,medicine ,Humans ,Prospective Studies ,Four-Dimensional Computed Tomography ,Adverse effect ,Aged ,Ultrasonography ,Bladder cancer ,medicine.diagnostic_test ,business.industry ,Ultrasound ,Hematology ,Cystoscopy ,Middle Aged ,medicine.disease ,Tumor detection ,Urinary Bladder Neoplasms ,Female ,Radiology ,Cardiology and Cardiovascular Medicine ,business ,Contrast-enhanced ultrasound - Abstract
PURPOSE The evaluation of the potential clinical benefit of four-dimensional ultrasound (4D-US) in the assessment of bladder cancer (BC). MATERIAL AND METHODS 20 patients with indication for cystoscopy for suspicion of bladder cancer were prospectively included in this study. All patients underwent two-dimensional ultrasound (2D-US), contrast enhanced ultrasound (CEUS) and real-time four-dimensional ultrasound (4D-US). All acquisitions were compared to each other in regard to image quality. This assessment was done using a 6 point scale (1 = best). All patients underwent subsequently cystoscopy with resection of the tumor (TURB), due a histopathological analysis was possible. RESULTS All examinations were performed successfully and no patient had to be excluded from the study. Patients acceptance of 4D-US was consistently good. No adverse events occurred. Image quality of real time 4D-US (score: 1.27±0.46) was significantly superior (p
- Published
- 2019
42. Die Striktur der vesikourethralen Anastomose nach radikaler Prostatektomie
- Author
-
Michael Chaloupka, Vincent Beck, Frank Strittmatter, Stefan Tritschler, Maria Apfelbeck, and Alexander Kretschmer
- Subjects
Gynecology ,03 medical and health sciences ,medicine.medical_specialty ,0302 clinical medicine ,Prostatectomy ,business.industry ,030220 oncology & carcinogenesis ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Vesicourethral anastomosis ,medicine ,business - Abstract
Die Striktur der vesikourethralen Anastomose ist eine schwerwiegende Komplikation nach radikaler Prostatektomie. Bisher konnten keine eindeutigen klinischen Faktoren fur die Entstehung einer Anastomosenstriktur sicher eruiert werden. Eine Striktur der vesikourethralen Anastomose tritt bei ca. 5–8 % aller Prostatektomiepatienten auf. Die klinische Symptomatik zeigt meist, ahnlich wie bei der benignen Prostatahyperplasie, eine irritative oder obstruktive Komponente. Selten kommt es in Folge einer Anastomosenstriktur zur Ausbildung einer teilweisen oder kompletten Belastungsinkontinenz. Die Diagnostik orientiert sich im Wesentlichen dem Vorgehen bei Harnrohrenstrikturen. Neben einer Uroflowmetrie sowie Restharnbestimmung kann zur weiteren Abklarung ein Zystourethrogramm ggf. eine Miktionszystourethrographie durchgefuhrt werden. Sollte hierbei keine eindeutige Diagnose gesichert werden, kann eine Urethrozystoskopie Sicherheit schaffen. Meistens werden endoskopische Verfahren als operative Therapie durchgefuhrt. Hierbei wird neben der Sachse-Urethrotomie oder einer Dilatation meistens eine transurethrale Resektion der Anastomose vorgenommen. Alle Verfahren zeigen jedoch eine hohe Rezidivquote. Bei rezidivierenden Strikturen konnen offen-operative Verfahren und hierbei meistens perineale Reanastomosen durchgefuhrt werden. Endourologische Verfahren stellen eine gute Therapieoption dar. Aufgrund der hohen Rezidivquoten sollten offen-operative Verfahren fruhzeitig angeboten und ggf. durchgefuhrt werden.
- Published
- 2017
43. Diagnostischer Workup bei der Harnröhrenstriktur
- Author
-
Vincent Beck, C.G. Stief, Frank Strittmatter, Michael Chaloupka, Stefan Tritschler, and Alexander Kretschmer
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,Urethral stricture ,business.industry ,Urology ,Entire urinary tract ,030232 urology & nephrology ,Urinary incontinence ,Cystoscopy ,urologic and male genital diseases ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Urethra ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,medicine ,Dysuria ,Radiology ,medicine.symptom ,Presentation (obstetrics) ,business ,Pyelogram - Abstract
Urethral stricture is a narrowing of the urethra due to scar tissue. It causes obstructive voiding dysfunction and can lead to long-term damage of the entire urinary tract. The probability of therapeutic success is dampened by a high rate of recurrence. Therefore, a careful taking of the patient's history and further diagnostics are crucial for finding the appropriate form of therapy. This review highlights the clinical presentation and diagnostic workup of urethral strictures.
- Published
- 2017
44. 68 Gallium–Prostate-Specific Membrane Antigen PET/Computed Tomography for Primary and Secondary Staging in Prostate Cancer
- Author
-
Christian Gratzke, Christian G. Stief, Michael Chaloupka, Clemens C. Cyran, Annika Herlemann, Harun Ilhan, and Melvin D'Anastasi
- Subjects
Biochemical recurrence ,Oncology ,medicine.medical_specialty ,PET-CT ,medicine.diagnostic_test ,business.industry ,Urology ,Computed tomography ,urologic and male genital diseases ,medicine.disease ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Psma pet ,medicine ,Glutamate carboxypeptidase II ,Recurrent disease ,Radiology ,Prostate cancer staging ,business - Abstract
Prostate-specific membrane antigen (PSMA) PET has been recently introduced for the diagnosis of patients with metastatic prostate cancer (PCa). Until today, staging of patients with PCa relied mostly on morphologic features, such as size or shape, resulting in low detection rates in disease recurrence. PSMA PET imaging provides molecular information and, in combination with conventional imaging, offers improved sensitivity and specificity. This review discusses the benefits and limitations of PSMA imaging in the setting of primary staging and detection of recurrent disease in comparison with standard-of-care imaging techniques.
- Published
- 2017
45. Akute Nierenkolik
- Author
-
Michael Chaloupka, Lennert Eismann, and Christian G. Stief
- Subjects
medicine.medical_specialty ,Acute Renal Colic ,business.industry ,Internal medicine ,MEDLINE ,Medicine ,General Medicine ,business ,Gastroenterology - Published
- 2021
46. Correction to: Health-related quality of life after open and robot-assisted radical prostatectomy in low- and intermediate-risk prostate cancer patients: a propensity score-matched analysis
- Author
-
Alexander Kretschmer, Robert Bischoff, Michael Chaloupka, Friedrich Jokisch, Thilo Westhofen, Philipp Weinhold, Frank Strittmatter, Armin Becker, Alexander Buchner, and Christian G. Stief
- Subjects
Male ,Prostatectomy ,Robotic Surgical Procedures ,Urology ,Quality of Life ,Correction ,Humans ,Prostatic Neoplasms ,Self Report ,Middle Aged ,Propensity Score ,Risk Assessment ,Retrospective Studies - Abstract
Introduction of robot-assisted radical prostatectomy (RARP) has revolutionized the therapeutic landscape of organ-confined prostate cancer (PCa). However, comparative analyses focused on health-related quality of life (HRQOL) after RARP and open retropubic prostatectomy (ORP) are sparse.In the current retrospective analysis, inclusion criteria encompassed PSA ≤ 10 ng/ml, ≤ pT2c, ISUP ≤ 3, age ≤ 65 years, and preoperative continence. A propensity score-matched patient cohort [n = 418 (ORP: 209, RARP: 209)] was created and HRQOL was prospectively assessed based on validated questionnaires (EORTC QLQ-C30) preoperatively, 3 months, 12 months, and 24 months postoperatively. Primary endpoint was good general HRQOL based on previously published cut-off values. Erectile function was measured via IIEF-5, urinary continence via ICIQ-SF questionnaire. Multivariable analysis included binary logistic regression models (p 0.05).Open retropubic prostatectomy and RARP cohorts were well balanced. General HRQOL was significantly higher for ORP compared to RARP after 3 months (70.1 vs. 61.6, p = 0.001), but not at the remaining follow-up time points. There were no significant differences for the remaining QLQ-C30 functioning and symptom scores. In multivariable analysis stratified for IIEF-5 and ICIQ-SF scores and surgeon experience, RARP could be confirmed as a marginally independent predictor for lower ratios of good general HRQOL after 3 months (OR 0.464, 95% CI 0.215-0.999; p = 0.050) without any differences at the remaining time points.The current study addresses various HRQOL outcomes over a postoperative period of up to 2 years in a homogenous propensity score-matched contemporary cohort. Marginally better general HRQOL outcomes could be detected for ORP compared to RARP 3 months postoperatively.
- Published
- 2021
47. Correction to: Impact of previous transurethral prostate surgery on health-related quality of life after radical prostatectomy: Does the interval between surgeries matter?
- Author
-
Alexander Buchner, Michael Chaloupka, Christian G. Stief, Paulo Pfitzinger, Franka Figura, Friedrich Jokisch, Alexander Kretschmer, Steffen Ormanns, Frank Strittmatter, Giuseppe Magistro, Boris Schlenker, Armin J. Becker, Philipp Weinhold, Robert Bischoff, and Thilo Westhofen
- Subjects
Male ,Reoperation ,medicine.medical_specialty ,Time Factors ,Multivariate analysis ,Urology ,medicine.medical_treatment ,Prostatic Hyperplasia ,030232 urology & nephrology ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,medicine ,Humans ,Propensity Score ,Aged ,Retrospective Studies ,Transurethral resection of the prostate ,Prostatectomy ,Urinary continence ,Proportional hazards model ,business.industry ,Transurethral Resection of Prostate ,Correction ,Middle Aged ,030220 oncology & carcinogenesis ,Cohort ,Quality of Life ,Prostate surgery ,business - Abstract
To assess the impact of previous transurethral surgery for benign prostate enlargement (BPE) and time interval between procedures on functional outcomes and health-related quality of life (HRQOL) after radical prostatectomy (RP). A propensity score-matched patient cohort [n = 685, (513 without previous BPE surgery, 172 with BPE surgery)] was created and HRQOL was pre- and postoperatively assessed using validated questionnaires (EORTC QLQ-C30). Urinary continence was measured via ICIQ-SF questionnaire and pad usage. Multivariable analysis included binary logistic and Cox regression models (p
- Published
- 2021
48. Added value of randomized biopsy to mpMRI-targeted biopsy of the prostate: 5-year experience from a community-based urologic outpatient clinic
- Author
-
C.G. Stief, Maria Apfelbeck, Robert Bischoff, Michael Chaloupka, Boris Schlenker, D-A. Clevert, L. Rath, Paulo Pfitzinger, and Alexander Buchner
- Subjects
Community based ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Urology ,General surgery ,Targeted biopsy ,medicine.anatomical_structure ,Prostate ,Biopsy ,medicine ,Added value ,Outpatient clinic ,business - Published
- 2021
49. Die zytoreduktive radikale Prostatektomie beim metastasierten Prostatakarzinom
- Author
-
Annabel Spek, Annika Herlemann, Christian Gratzke, Michael Chaloupka, and C.G. Stief
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Prostatectomy ,Urology ,medicine.medical_treatment ,Brachytherapy ,030232 urology & nephrology ,Bone metastasis ,Malignancy ,medicine.disease ,Primary tumor ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,In patient ,business ,Prospective cohort study - Abstract
The resection of the primary tumor in patients with metastatic prostate cancer is controversially debated. Retrospective clinical studies indicate survival benefits and prevention of secondary, locoregional complications; however, results of ongoing multicenter prospective studies are still lacking. This review highlights the rationale behind the cytoreductive prostatectomy and summarizes current clinical study results.
- Published
- 2017
50. Die radikale Prostatektomie als Teil der multimodalen Therapie
- Author
-
Christian Gratzke, Michael Chaloupka, Christian G. Stief, and Annika Herlemann
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,medicine ,business - Abstract
Lange Zeit war die radikale Prostatektomie keine Option zur Therapie des metastasierten Prostatakarzinoms. Es gibt aber immer mehr Hinweise, dass gut selektierte Patienten mit diesen Tumoren davon profitieren konnen. In den kommenden Jahren werden Ergebnisse aus randomisiert-kontrollierten Studien die Rolle der radikalen Prostatektomie als Teil der multimodalen Behandlung des metastasierten Prostatakarzinoms besser charakterisieren.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.